Presentation is loading. Please wait.

Presentation is loading. Please wait.

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide 

Published byVeronika Kusumo Modified over 5 years ago

Similar presentations

Presentation on theme: "HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide "— Presentation transcript:

1 HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide  Leo Luznik, Paul V. O'Donnell, Heather J. Symons, Allen R. Chen, M. Susan Leffell, Marianna Zahurak, Ted A. Gooley, Steve Piantadosi, Michele Kaup, Richard F. Ambinder, Carol Ann Huff, William Matsui, Javier Bolaños-Meade, Ivan Borrello, Jonathan D. Powell, Elizabeth Harrington, Sandy Warnock, Mary Flowers, Robert A. Brodsky, Brenda M. Sandmaier, Rainer F. Storb, Richard J. Jones, Ephraim J. Fuchs  Biology of Blood and Marrow Transplantation  Volume 14, Issue 6, Pages (June 2008) DOI: /j.bbmt Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Nonmyeloablative haploidentical BMT conditioning and postgrafting immunosuppresive regimen. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Engraftment and chimerism. Cumulative incidence of (A) neutrophil and (B) platelet engraftment. Dashed line represents death without engraftment (competing risk). (C) Percentage of donor chimerism at days and In Seattle, donor chimerism was analyzed from the CD3+ and CD33+ fractions of peripheral blood, whereas in Baltimore donor chimerism was analyzed from whole peripheral blood or bone marrow. Bone marrow samples were not obtained from all evaluable patients. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Cumulative incidence of aGVHD and cGVHD. (A) Cumulative incidence of aGVHD grades II-IV and III-IV. (B) Cumulative incidence of extensive cGVHD for patients who received 1 (Seattle) versus 2 (Baltimore) doses of posttransplant Cy. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 Outcomes among nonmyeloablative haploidentical BMT recipients. (A) Cumulative incidence of NRM and relapse. (B) OS and EFS. (C) EFS, according to disease category (myeloid versus lymphoid). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide "

Similar presentations

Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative.

Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative.
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.
Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia.

Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia.
Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Impact of Postgrafting Immunosuppressive Regimens on Nonrelapse Mortality and Survival after Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant.

Impact of Postgrafting Immunosuppressive Regimens on Nonrelapse Mortality and Survival after Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant.
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia  Robert Iannone, James F Casella, Ephraim.

Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia  Robert Iannone, James F Casella, Ephraim.
KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.
Comparison of Allogeneic Stem Cell Transplantation from Familial- Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk.

Comparison of Allogeneic Stem Cell Transplantation from Familial- Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk.
Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post- Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-

Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post- Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.
Carol Ann Huff, Ephraim J. Fuchs, B

Carol Ann Huff, Ephraim J. Fuchs, B
Posttransplant Autoimmune Hemolytic Anemia and Other Autoimmune Cytopenias are Increased in Very Young Infants Undergoing Unrelated Donor Umbilical Cord.

Posttransplant Autoimmune Hemolytic Anemia and Other Autoimmune Cytopenias are Increased in Very Young Infants Undergoing Unrelated Donor Umbilical Cord.
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,
Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation  Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan.

Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation  Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan.
Ephraim J. Fuchs, Xiao-jun Huang, Jeffrey S. Miller 

Ephraim J. Fuchs, Xiao-jun Huang, Jeffrey S. Miller 
T Cell–Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar.

T Cell–Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar.

Similar presentations

Ads by Google